CD8A and neoplasm: After co-culturing PKM2 knockdown T24 or UMUC3 cells with CD8+ T cells for 72 h, the anti-tumour ability of CD8+ T cells and immunotherapy sensitivity of BCa were significantly promoted (Additional figure S3E–F).